PMID- 16829981 OWN - NLM STAT- MEDLINE DCOM- 20060829 LR - 20250214 IS - 1471-0072 (Print) IS - 1471-0072 (Linking) VI - 7 IP - 7 DP - 2006 Jul TI - EGF-ERBB signalling: towards the systems level. PG - 505-16 AB - Signalling through the ERBB/HER receptors is intricately involved in human cancer and already serves as a target for several cancer drugs. Because of its inherent complexity, it is useful to envision ERBB signalling as a bow-tie-configured, evolvable network, which shares modularity, redundancy and control circuits with robust biological and engineered systems. Because network fragility is an inevitable trade-off of robustness, systems-level understanding is expected to generate therapeutic opportunities to intercept aberrant network activation. FAU - Citri, Ami AU - Citri A AD - Department of Biological Regulation, the Weizmann Institute of Science, 1 Hertzl Street, Rehovot 76100, Israel. FAU - Yarden, Yosef AU - Yarden Y LA - eng PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Review PL - England TA - Nat Rev Mol Cell Biol JT - Nature reviews. Molecular cell biology JID - 100962782 RN - 0 (Ligands) RN - 0 (Oncogene Proteins v-erbB) RN - 62229-50-9 (Epidermal Growth Factor) RN - EC 2.7.1.- (Phosphatidylinositol 3-Kinases) RN - EC 2.7.10.1 (ErbB Receptors) SB - IM MH - Animals MH - Endocytosis/physiology MH - Epidermal Growth Factor/*metabolism MH - ErbB Receptors/chemistry/genetics/metabolism MH - Feedback, Physiological MH - Humans MH - Ligands MH - Models, Molecular MH - Oncogene Proteins v-erbB/genetics/*metabolism MH - Phosphatidylinositol 3-Kinases/metabolism MH - Protein Conformation MH - Signal Transduction/*physiology RF - 142 EDAT- 2006/07/11 09:00 MHDA- 2006/08/30 09:00 CRDT- 2006/07/11 09:00 PHST- 2006/07/11 09:00 [pubmed] PHST- 2006/08/30 09:00 [medline] PHST- 2006/07/11 09:00 [entrez] AID - nrm1962 [pii] AID - 10.1038/nrm1962 [doi] PST - ppublish SO - Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16. doi: 10.1038/nrm1962.